Article
Chemistry, Medicinal
Li Zhang, Xin-Mei Yang, Jing Chen, Lei Hu, Fan Yang, Yue Zhou, Bei-Bei Zhao, Wei Zhao, Xiao-Fan Zhu
Summary: The pharmacokinetics and safety of the oral AS(4)S(4) formula were evaluated for the first time in pediatric APL patients. The dosing regimen of 60 mg/kg/d TID resulted in a higher steady-state through concentration in children than in adults, showing it to be safe and effective.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Oncology
Yu Zheng, Yuan-Fei Mao, Hui-Jin Zhao, Li Chen, Li-Ning Wang, Yun-Xiang Zhang, Jiong Hu, Jun-Min Li, Xiao-Yang Li, Hong-Ming Zhu
Summary: This study investigated the arsenic metabolism in APL patients who completed ATO treatment and found a decreased arsenic methylation capacity after treatment. The increased proportion of iAs(III) in urine was associated with chronic liver toxicity, highlighting the importance of monitoring urine PMI and considering SNPs of the AS3MT gene in determining ATO dosage.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Review
Chemistry, Medicinal
Guangzhi Liu, Yurong Song, Chenxi Li, Rui Liu, Youwen Chen, Liuchunyang Yu, Qingcai Huang, Dongjie Zhu, Cheng Lu, Xue Yu, Cheng Xiao, Yuanyan Liu
Summary: Arsenic and its compounds have been utilized for nearly 4000 years, showing important therapeutic roles in treating diseases like acute promyelocytic leukemia. However, long-term exposure to arsenic may have detrimental health effects, particularly carcinogenesis.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Zhuo Zhang, Shunji Zhang, Fan Zhang, Qian Zhang, Hong Wei, Ruolin Xiu, Yanhong Zhao, Meijuan Sui
Summary: This study aimed to explore noninvasive clinical indicators that can guide the individualized use of arsenic trioxide (ATO) in the future. The results revealed that hemoglobin >= 80 g/L, nonprophylactic hepatoprotective agents, non-single-agent ATO, and decreased fibrinogen < 1 g/L were risk factors for ATO-induced hepatotoxicity in newly diagnosed APL patients.
BIOLOGICAL TRACE ELEMENT RESEARCH
(2023)
Article
Medicine, Research & Experimental
Jian Lv, Mengliang Wu, Chunrong Pang, Rui Duan, Hong Zhang, Shuo Tian, Haixia Yang, Xin Hai
Summary: Torsemide increased the plasma concentrations of arsenic metabolites in APL patients treated with ATO by inhibiting the transporter MRP4 in a dose-dependent manner. This effect was also observed in rats treated with both ATO and torsemide. Torsemide reduced the excretion of arsenic in urine and increased its concentration in the kidneys of rats.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Li Chen, Hong-Ming Zhu, Yan Li, Qi-Fa Liu, Yu Hu, Jian-Feng Zhou, Jie Jin, Jian-Da Hu, Ting Liu, De-Pei Wu, Jie-Ping Chen, Yong-Rong Lai, Jian-Xiang Wang, Juan Li, Jian-Yong Li, Xin Du, Xin Wang, Ming-Zhen Yang, Jin-Song Yan, Gui-Fang Ouyang, Li Liu, Ming Hou, Xiao-Jun Huang, Xiao-Jing Yan, Dan Xu, Wei-Ming Li, Deng-Ju Li, Yin-Jun Lou, Zheng-Jun Wu, Ting Niu, Ying Wang, Xiao-Yang Li, Jian-Hua You, Hui-Jin Zhao, Yu Chen, Yang Shen, Qiu-Sheng Chen, Jian Li, Bing-Shun Wang, Wei-Li Zhao, Jian-Qing Mi, Kan-Kan Wang, Jiong Hu, Zhu Chen, Sai-Juan Chen, Jun-Min Li
Summary: This study found that the combination of all-trans retinoic acid and arsenic trioxide in treating acute promyelocytic leukemia during consolidation therapy is not inferior to traditional chemotherapy regimens and shows better outcomes in reducing relapse and toxicity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Letter
Oncology
Ya-Fang Ma, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, Li-Ping Mao, Gai-Xiang Xu, Li Li, Jian Huang, Huai-Yu Wang, Li-Jiang Lou, Hai-Tao Meng, Jie-Jing Qian, Wen-Juan Yu, Ju-Ying Wei, Zhen-Yu Li, Xue-Lu Zhu, Xiao-Yan Yan, Su-Ning Chen, Jie Jin, Hong-Hu Zhu
Summary: Oral arsenic plus ATRA without chemotherapy is an effective first-line consolidation therapy for high-risk APL patients, with mild to moderate adverse events.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Cell Biology
Junfen Xu, Yuanming Shen, Conghui Wang, Sangsang Tang, Shiyuan Hong, Weiguo Lu, Xing Xie, Xiaodong Cheng
Summary: Combination therapy of PARP inhibitors and arsenic compound shows significant therapeutic effects in HR-proficient ovarian cancer, including suppression of cell proliferation, induction of DNA damage, and promotion of apoptosis.
CELL DEATH DISCOVERY
(2021)
Article
Environmental Sciences
Mengliang Wu, Chunrong Pang, Shengwen Lu, Thomas H. Hostetter, Xin Hai
Summary: Our study investigated the impact of type 2 diabetes (T2DM) on arsenic metabolism in acute promye-locytic leukemia (APL) patients treated with arsenic trioxide. We discovered that APL patients with T2DM had significantly higher concentrations of arsenic metabolites compared to non-diabetic patients, and this increase was positively correlated with blood glucose levels. Additionally, APL patients with T2DM were more susceptible to liver injury and QTc interval prolongation due to altered arsenic methylation capacity. In in vitro experiments, we cultured HEK293T cells under different glucose concentrations and observed higher concentrations of arsenic metabolites in cells with high glucose. Moreover, high glucose levels significantly increased the expression of the arsenic uptake transporter AQP7 in HEK293T cells at the mRNA and protein levels. Overall, our study demonstrated that T2DM can lead to elevated concentrations of arsenic metabolites in APL patients by increasing AQP7 expression.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2023)
Article
Oncology
Francesco Autore, Patrizia Chiusolo, Federica Sora, Sabrina Giammarco, Luca Laurenti, Idanna Innocenti, Elisabetta Metafuni, Nicola Piccirillo, Livio Pagano, Simona Sica
Summary: Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterized by t(15;17) and PML/RAR alfa fusion gene. Treatment with a combination of all-trans retinoic acid and arsenic trioxide has shown high efficacy and tolerability, providing an alternative to chemotherapy for selected patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yanfeng Liu, Yan Jia, Yi Liu, Xuefeng Chen, Mei Zhang
Summary: This study confirms the potential of tetra-arsenic tetra-sulfide (As4S4) as an adjuvant for NK-92MI in the treatment of ATRA-resistant APL.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Pharmacology & Pharmacy
Shiyi Xu, Xinyu Zhang, Xingyu Zhu, Hui Su, Xueying Yan
Summary: Co-loading nanoparticle encapsulation is an effective strategy for anti-tumor treatment. The combination of arsenic trioxide and tetrandrine synergistically inhibits tumor growth and metastasis. This study developed co-loading nanoparticle formulations and demonstrated their improved drug distribution and anti-tumor activity.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Toxicology
Chunlu Gao, Liwang Lin, Jing Li, Mengliang Wu, Jian Lv, Shuo Tian, Xin Hai
Summary: This study identifies the binding sites of arsenic on hemoglobin in acute promyelocytic leukemia (APL) patients after arsenic trioxide (As2O3) treatment. Arsenic accumulates in erythrocytes by binding to Cys-104 alpha and Cys-112 beta in hemoglobin. Understanding this interaction could contribute to the therapeutic effect of As2O3 as an anticancer drug and its toxicity on APL patients.
TOXICOLOGY LETTERS
(2023)
Article
Oncology
Cristina M. Ghiuzeli, Miroslav Styblo, Jesse Saunders, Anthony Calabro, Daniel Budman, Steven Allen, Craig Devoe, Radhika Dhingra
Summary: The study found that the metabolism of arsenic trioxide (ATO) in patients with Acute Promyelocytic Leukemia (APL) is influenced by smoking and previous chemotherapy exposure. Different patients exhibited distinct patterns of iAs metabolism, which could impact the effective dose of ATO.
LEUKEMIA & LYMPHOMA
(2022)
Review
Medicine, Research & Experimental
Jie Wang, Yong -Mei Liu, Jun Hu, Cong Chen
Summary: Over the past few decades, clinical trials have shown the efficacy of arsenic trioxide (ATO) in treating relapsed acute promyelocytic leukemia (APL). However, its use is limited by cardiac side effects. This article discusses the mechanism of ATO-induced cardiac side effects, reviews studies on ATO and APL, and summarizes the protective effects of natural products in treating ATO-induced cardiac side effects. Natural products show promise in developing cardioprotective agents against ATO-induced cardiac side effects.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Hematology
Shenmiao Yang, Rong Zhu, Nan Li, Yu Feng, Rui Zuo, Robert Peter Gale, Xiaojun Huang
Summary: This study demonstrated that in CLL/SLL patients, including those with HBV infection, ibrutinib is safer and more effective than rituximab, with similar outcomes in Asian and European populations.
ACTA HAEMATOLOGICA
(2022)
Review
Hematology
Shenmiao Yang, Xiaojun Huang, Robert Peter Gale
Summary: There has been significant progress in the treatment of chronic lymphocytic leukemia (CLL), largely due to the development of new drugs. However, current therapies are unable to cure the majority of CLL patients. Two types of cell therapies, hematopoietic cell transplants and chimeric antigen receptor (CAR)-T cells, are currently being evaluated or re-evaluated in the context of these advancements. We discuss the potential role of these cell therapies in the evolving treatment landscape of CLL, including their mechanisms of action and appropriate candidates for cell therapy.
Article
Immunology
Qian-Nan Shang, Xing-Xing Yu, Zheng-Li Xu, Xun-Hong Cao, Xue-Fei Liu, Xiao-Su Zhao, Ying-Jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiang-Yu Zhao
Summary: This study finds that DNAM-1 expression correlates with the functional competence of human NK cells through the KIR/MHC-I interaction. NK cells with donor or recipient HLA molecules regulate DNAM-1 expression, thereby affecting NK cell education. The effects of recipient cells on NK cell education are greater, and activating receptors may collaborate with DNAM-1 to induce educated NK cell hyperresponsiveness.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ru Feng, Yi Liu, Xiao-Lu Zhu, Wan-Yi Zhai, Yun He, Hai-Xia Fu, Qian Jiang, Hao Jiang, Jin Lu, Hui Liu, Jing-Wen Wang, Hao Wang, Yan-Di Xie, Hui Ma, Xiao-Jun Huang, Xiao-Hui Zhang
Summary: This study aimed to explore the efficacy and safety of recombinant human thrombopoietin (rhTPO) in the treatment of hepatitis B-related cirrhosis complicated with severe thrombocytopenia. The results showed that treatment with rhTPO and/or prednisone could increase platelet counts and reduce bleeding events, especially in patients without splenomegaly.
JOURNAL OF VIRAL HEPATITIS
(2022)
Article
Oncology
Jun Wang, Feng-Ting Dao, Yu Wang, Hao Jiang, Lan-Ping Xu, Xiao-Su Zhao, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin
Summary: This study investigated the benefits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for inv(16) acute myeloid leukemia (AML) patients in first complete remission (CR1) based on the combination of mutation status and minimal residual disease (MRD) levels. The results showed that allo-HSCT significantly improved both the cumulative incidence of relapse (CIR) and overall survival (OS) for high-risk patients, had a favorable effect on CIR for intermediate-risk patients, and had no significant effect on CIR and OS for low-risk patients.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Hematology
Nan Xu, Yue-Yun Lai, Wen-Min Chen, Hao Jiang, Yu Wang, Xu Wang, Xiao-Su Zhao, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin
Summary: Adult CK-AML patients have varied risks and TP53 mutations seem to be an independent adverse prognostic factor.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2022)
Correction
Oncology
Yan Su, Xueyan Sun, Xiao Liu, Qingyuan Qu, Liping Yang, Qi Chen, Fengqi Liu, Yueying Li, Qianfei Wang, Bo Huang, Xiao-Hui Zhang, Xiao-Jun Huang
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Yan Su, Xueyan Sun, Xiao Liu, Qingyuan Qu, Liping Yang, Qi Chen, Fengqi Liu, Yueying Li, Qianfei Wang, Bo Huang, Xiao-Hui Huang, Xiao-Jun Zhang
Summary: In this study, ATO-loaded hUC-EVs (hUC-EVs-ATO) were prepared and found to significantly alleviate clinical manifestations and histological scores of aGVHD in mice, prolonging their survival. Mechanistically, hUC-EVs-ATO induced autophagic flux by inhibiting mTOR activity, leading to repolarization of M1 to M2 macrophages. These findings suggest that hUC-EVs-ATO could be a promising therapeutic approach for aGVHD.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Letter
Biophysics
Lanping Xu, Yue Lu, Jing Chen, Shuwen Sun, Shaoyan Hu, Shunqing Wang, Xuedong Wu, Yuan Sun, Dingming Wan, Yajing Xu, Hui Jiang, Chunfu Li, Mei Lan, Erlie Jiang, Fei Li, Sixi Liu, Yongmin Tang, Fan Lin, Peihua Lu, Chengjuan Luo, Xiaojun Huang
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Cuiyan Zhou, Fengmei Zheng, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Yuewen Wang, Xiaodong Mo, Yifei Cheng, Yuhong Chen, Meng Lv, Fengrong Wang, Chenhua Yan, Wei Han, Huan Chen, Lanping Xu, Yu Wang, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang, Yingjun Chang
Summary: CD34(+) cell dose has an impact on hematopoietic recovery in ALL patients, especially in pre-HSCT MRD-positive patients, where higher CD34(+) cell doses are associated with faster neutrophil and platelet engraftment. However, we did not observe direct correlations between CD34(+) cell dose and relapse, TRM, LFS, or OS.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Biology
Qi Wen, Zheng-Li Xu, Yu Wang, Meng Lv, Yang Song, Zhong-Shi Lyv, Tong Xing, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong
Summary: This study found that glycolysis plays a critical role in T cell activation and induction of human aGvHD. Regulating glycolysis offers a potential pathogenesis-oriented therapeutic strategy for aGvHD patients, and the combination of GCs and glycolysis inhibitors may be a novel first-line combination therapy for aGvHD patients.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Letter
Biophysics
Ming Wang, Bixia Wang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Yi-fei Cheng, Yu-Qian Sun, Yuan-Yuan Zhang, Yan-Rong Liu, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Ting Huang, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: This study compared the clinical outcomes of AML patients with and without TP53 mutations who underwent haplo-HSCT, and found no significant differences in 2-year clinical outcomes between the two groups. Multivariable analysis also showed that TP53 mutations had no significant impact on relapse rate, mortality rate, overall survival, graft-versus-host disease, leukemia-free survival or GvHD-free/relapse-free survival. The findings suggest that patients with AML with TP53 mutations may at least partially benefit from haplo-HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Xin-Xin Liu, Xin-An Pan, Meng-Ge Gao, Jun Kong, Hao Jiang, Ying-Jun Chang, Xiao-Hui Zhang, Yu Wang, Kai-Yan Liu, Zhong Chen, Xiao-Su Zhao, Xiao-Jun Huang
Summary: This study found that EVI1 high expression was associated with poor prognosis in the Non-KMT2A-MLLT3 group and both KMT2A-MLLT3 and Non-KMT2A-MLLT3 patients who received chemotherapy alone had poorer prognosis than those who received allogeneic hematopoietic stem cell transplant. High EVI1 expression was shown to have an adverse effect on AML with KMT2A rearrangement in different risk stratification subtypes.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)